Metoject® 50 mg/ml is a pre-filled syringe for injection containing the drug methotrexate. Metoject® 50 mg/ml is registered for the treatment of Active rheumatoid arthritis in adult patients, active juvenile idiopathic arthritis, severe recalcitrant disabling psoriasis, mild to moderate Crohn’s disease and is available in different doses. 

Pre-filled auto-injectors 7.5mg/0.15ml, 10mg/0.2ml, 12.5mg/0.25ml, 15mg/0.3ml, 20mg/0.4ml, 25mg/0.5ml.

Metoject Pen is indicated for the treatment of 

• active rheumatoid arthritis in adult patients,
• polyarthritic forms of severe, active juvenile idiopathic arthritis, when the response to nonsteroidal anti-inflammatory drugs (NSAIDs) has been inadequate,
• severe recalcitrant disabling psoriasis, which is not adequately responsive to other forms of therapy such as phototherapy, PUVA, and retinoids, and severe psoriatic arthritis in adult patients.
• mild to moderate Crohn’s disease either alone or in combination with corticosteroids in adult patients refractory or intolerant to thiopurines.

Tablets 10mg, 15mg, 20mg

Leflunomide is indicated for the treatment of adult patients with:

• active rheumatoid arthritis as a “disease-modifying antirheumatic drug” (DMARD).
• active psoriatic arthritis.